Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 43.14% is in line with its 5-year average of 42.24%, near the high end of its 5-year range (36.25%–45.47%).
1.06% above its 12-month average of 42.69%.
Reported quarterly EBITDA margin; no daily interpolation.
EBITDA MARGIN
43.14%
EBITDA MARGIN AVG TTM
42.69%
EBITDA MARGIN AVG 3Y
43.02%
EBITDA MARGIN AVG 5Y
42.24%
EBITDA MARGIN AVG 10Y
39.67%
EBITDA MARGIN AVG 15Y
33.98%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.06%
CURRENT VS 3Y AVG
+0.27%
CURRENT VS 5Y AVG
+2.13%
CURRENT VS 10Y AVG
+8.74%
CURRENT VS 15Y AVG
+26.96%
CURRENT VS 20Y AVG
N/A
Market Cap
$31.10B
EBITDA Margin
16.19%
TTM Avg
16.24%
3Y Avg
16.31%
5Y Avg
17.37%
Market Cap
$30.62B
EBITDA Margin
34.73%
TTM Avg
34.58%
3Y Avg
34.05%
5Y Avg
33.84%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zoetis Inc. (ZTS) | $31.78B | 43.14% | 42.69% | 43.02% | 42.24% |
| GE HealthCare Technologies Inc. (GEHC)vs › | $31.10B | 16.19% | 16.24% | 16.31% | 17.37% |
| Medline Inc. (MDLN)vs › | $30.94B | 10.26% | 11.41% | 10.38% | 10.38% |
| Biogen Inc. (BIIB)vs › | $32.63B | 28.67% | 30.68% | 30.30% | 31.44% |
| Waters Corporation (WAT)vs › | $30.62B | 34.73% | 34.58% | 34.05% | 33.84% |
| Centene Corp. (CNC)vs › | $33.12B | -3.26% | -0.27% | 1.02% | 1.75% |
| ResMed Inc. (RMD)vs › | $33.12B | 36.98% | 37.16% | 34.64% | 34.36% |
| DexCom, Inc. (DXCM)vs › | $33.17B | 24.96% | 22.62% | 21.42% | 19.95% |
| Alcon Inc. (ALC)vs › | $34.38B | 24.53% | 25.59% | 24.02% | 22.67% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $35.61B | 15.00% | 4.83% | -18.55% | -52.26% |
Gross Margin
70.9%
EBITDA Margin
43.1%
Operating Margin
37.0%
Net Margin
27.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 42.79% |
| 2026-03-31 | 41.60% |
| 2025-12-31 | 39.67% |
| 2025-09-30 | 44.17% |
| 2025-06-30 | 45.20% |
| 2025-03-31 | 43.47% |
| 2024-12-31 | 38.33% |
| 2024-09-30 | 43.59% |
| 2024-06-30 | 43.75% |
| 2024-03-31 | 42.33% |
| 2023-12-31 | 37.73% |
| 2023-09-30 | 42.86% |
| 2023-06-30 | 43.81% |
| 2023-03-31 | 42.40% |
| 2022-12-31 | 39.66% |
| 2022-09-30 | 41.86% |
| 2022-06-30 | 41.08% |
| 2022-03-31 | 45.47% |
| 2021-12-31 | 36.25% |
| 2021-09-30 | 42.11% |
| 2021-06-30 | 42.92% |
| 2021-03-31 | 46.18% |
| 2020-12-31 | 34.42% |
| 2020-09-30 | 43.39% |
| 2020-06-30 | 42.89% |
| 2020-03-31 | 42.31% |
| 2019-12-31 | 36.38% |
| 2019-09-30 | 42.36% |
| 2019-06-30 | 40.34% |
| 2019-03-31 | 36.15% |
| 2018-12-31 | 30.37% |
| 2018-09-30 | 41.42% |
| 2018-06-30 | 38.66% |
| 2018-03-31 | 35.43% |
| 2017-12-31 | 36.44% |
| 2017-10-01 | 38.83% |
| 2017-07-02 | 34.83% |
| 2017-04-02 | 34.93% |
| 2016-12-31 | 26.78% |
| 2016-10-02 | 32.07% |
| 2016-07-03 | 31.29% |
| 2016-04-03 | 31.67% |
| 2015-12-31 | 19.15% |
| 2015-09-27 | 27.02% |
| 2015-06-28 | 24.26% |
| 2015-03-29 | 24.86% |
| 2014-12-31 | 15.76% |
| 2014-09-28 | 23.88% |
| 2014-06-29 | 22.19% |
| 2014-03-30 | 25.07% |
| 2013-12-31 | 16.67% |
| 2013-09-29 | 20.49% |
| 2013-06-30 | 18.31% |
| 2013-03-31 | 22.11% |
| 2012-12-31 | 16.75% |
| 2012-09-30 | 26.40% |
| 2012-06-30 | 29.07% |
| 2012-03-31 | 23.50% |
| 2011-12-31 | 17.57% |
| 2011-09-30 | 24.12% |
| 2011-06-30 | 17.41% |
| 2011-03-31 | 20.24% |
